Pfizer and partner BioNTech announced they have submitted a request to the U.S. Food and Drug Administration (FDA) to authorize a COVID-19 vaccine booster that has been updated to target the newest Omicron subvariants.
The request comes after the FDA in June advised COVID-19 vaccine makers to amend their shots to target the two Omicron subvariants BA.4 and BA.5, which are better than ever at dodging immunity from earlier vaccination or infection.
“Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older,” the companies said in a release on Aug. 22….